A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and Elecsys Anti-HBc in a Korean population.

•We evaluated the clinical performance of Elecsys Anti-HBc II on 345 Korean samples.•The clinical sensitivity of Elecsys Anti-HBc II was 99.06%.•The clinical specificity of Elecsys Anti-HBc II was 100%.•The concordance rate between Elecsys Anti-HBc and Elecsys Anti-HBc II was 100%.•Elecsys Anti-HBc II is a reliable diagnostic device for HBV infection in Korea..